🇺🇸 FDA

Intelligence · Clinical Pipeline

Boehringer Ingelheim Pipeline

All ClinicalTrials.gov programs at Boehringer Ingelheim — phase, modality, and trial IDs.

Programs
193

Quick answer

Boehringer Ingelheim has 193 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity

    Boehringer Ingelheim

    Obesity

    phase 1 other active

    1 trial

  2. A study to compare how different medicines (rosuvastatin, digoxin, metformin, and furosemide) are handled by the body of healthy people and people with liver cirrhosis

    Boehringer Ingelheim

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    phase 1 other active

    1 trial

  3. A study to compare how different substances (caffeine, warfarin, omeprazole, metoprolol, and midazolam) are handled by the body of healthy people and people with liver cirrhosis

    Boehringer Ingelheim

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    phase 1 other active

    1 trial

  4. A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

    Boehringer Ingelheim

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 1 other active

    1 trial

  5. A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  6. A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  7. A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

  8. A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 other active

    1 trial

  9. A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  10. A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  11. A study to test how BI 3031185 is tolerated by people with borderline personality disorder or attention-deficit/hyperactivity disorder.

    Boehringer Ingelheim

    Attention deficit hyperactivity disorder, Borderline personality disorder

    phase 1 other active

    1 trial

  12. A study to test how BI 456906 is taken up in the blood of people with and without kidney problems

    Boehringer Ingelheim

    Renal impairment (mild, moderate and severe), Healthy

    phase 1 other active

    1 trial

  13. A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced solid tumours

    phase 1 other active

    1 trial

  14. A study to test how different doses of BI 3731579 are tolerated by healthy people

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  15. A study to test how different doses of BI 3814916 are tolerated by healthy people

    Boehringer Ingelheim

    healthy volunteer trial

    phase 1 other active

    1 trial

  16. A study to test how well different doses of BI 3031185 are tolerated by healthy men and women

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  17. A study to test how well different doses of BI 3034701 are tolerated by healthy men and people with overweight or obesity

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  18. A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH

    Boehringer Ingelheim

    Metabolic Dysfunction-associated Steatohepatitis

    phase 1 other active

    1 trial

  19. A study to test how well different doses of BI 3810477 are tolerated by healthy men

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  20. A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  21. A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3

    Boehringer Ingelheim

    Glioma expressing DLL3

    phase 1 other active

    1 trial

  22. A study to test how well healthy people tolerate spesolimab when given in 2 different ways.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  23. A study to test how well multiple doses of BI 3810477 are tolerated by healthy adults.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  24. A study to test how well multiple doses of BI 765423 are tolerated by healthy men

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  25. A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesity

    Boehringer Ingelheim

    Overweight, Obesity

    phase 1 other active

    1 trial

  26. A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer

    Boehringer Ingelheim

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

  27. A study to test whether multiple doses of BI 456906 have an effect on cardiac safety in people with overweight or obesity.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  28. A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone

    Boehringer Ingelheim

    Head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  29. BI 1015550, NERANDOMILAST

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 small molecule active

    1 trial

  30. BI 3011441

    Boehringer Ingelheim

    Solid Tumors, KRAS Mutation

    phase 1 small molecule completed

    1 trial

  31. BI 695502

    Boehringer Ingelheim

    Healthy

    phase 1 small molecule completed

    1 trial

  32. BI 765063

    Boehringer Ingelheim

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 1 small molecule active

    1 trial

  33. BI 905711

    Boehringer Ingelheim

    Gastrointestinal Neoplasms

    phase 1 small molecule completed

    1 trial

  34. Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)

    Boehringer Ingelheim

    Solid tumours with HER2 aberrations, Non-small cell lung cancer

    phase 1 other active

    1 trial

  35. DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy

    Boehringer Ingelheim

    relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  36. DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

    Boehringer Ingelheim

    Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

    phase 1 other active

    1 trial

  37. DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer

    Boehringer Ingelheim

    Extensive-stage small cell lung carcinoma (ES-SCLC)

    phase 1 other active

    1 trial

  38. KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

    Boehringer Ingelheim

    G12D/G12V Pancreatic Ductal Adenocarcinoma

    phase 1 other active

    1 trial

  39. Lendormin tablet

    Boehringer Ingelheim

    Healthy

    phase 1 small molecule completed

    1 trial

  40. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  41. Spesolimab

    Boehringer Ingelheim

    Psoriasis

    phase 1 small molecule completed

    1 trial

  42. This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  43. Volasertib, low dose, d1q3w

    Boehringer Ingelheim

    Neoplasms

    phase 1 small molecule completed

    1 trial

  44. Afatinib

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    approved small molecule completed

    1 trial

  45. Spesolimab

    Boehringer Ingelheim

    Generalized Pustular Psoriasis

    approved small molecule active

    3 trials

  46. Telmisartan

    Boehringer Ingelheim

    Cardiovascular Diseases

    approved small molecule completed

    1 trial

  47. metformin

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  48. telmisartan

    Boehringer Ingelheim

    Hypertension

    approved small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Boehringer Ingelheim have?

193 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.